Betalight Photodynamic Therapy is a novel procedure that uses a light-activated agent to gently target and restore function of the eye’s meibomian glands—those oil-producing structures in your eyelids that help prevent tear evaporation. The process involves applying a light-sensitive compound to the eyelid margin, followed by exposure to a specific wavelength of light that activates cellular repair and encourages oil production.
Direct Targeting of the Problem: Rather than relying on artificial tear supplements alone, Betalight PDT treats the underlying cause—dysfunctional meibomian glands.
Non-Invasive & Efficient: The therapy is performed in-office and typically completed in under 30 minutes, with minimal discomfort.
Early Clinical Success: Studies report significant improvements in tear film stability, decreased dryness, and enhanced comfort—even among patients who didn’t respond to first-line treatments.
The therapy shows particular promise for those with meibomian gland dysfunction (MGD)—a leading cause of evaporative dry eye.
It’s also being evaluated for contact lens wearers and post-refractive surgery patients, both groups commonly affected by tear film instability.
Researchers anticipate wider applications, such as combining light-based treatments with topical lubricants or in-office thermal therapies for enhanced results.
Betalight PDT represents an exciting leap forward in treating dry eye—not just masking symptoms but improving gland function at a biological level. As trials continue and validation grows, this innovative therapy has the potential to become a powerful tool in modern optometric care.